Case Report on Pasireotide in Neonatal Hyperinsulinism Published

A case report involving pasireotide was published on August 27, 2026, in Frontiers in Endocrinology. The publication is titled "Case Report: Pasireotide treatment in neonatal congenital hyperinsulinism due to a homozygous ABCC8 mutation." It describes a clinical case involving pasireotide treatment in a neonate with congenital hyperinsulinism linked to a homozygous ABCC8 mutation. The report is listed under PubMed ID 42723843. No outcome data, efficacy results, or safety findings from the case were provided beyond the publication's existence and title. Pasireotide remains an approved compound, and this publication represents a new addition to the case literature involving its use in a specific pediatric endocrine condition. Readers interested in the broader context of pasireotide, including its approved indications and prior clinical data, can consult the compound overview for additional background.